Epidemiology of clinical isolates of Candida albicans and their susceptibility to triazoles.

Int J Antimicrob Agents

Department of Medical Microbiology, Medical University in Warsaw, 5 Chalubinskiego Street, 02-004 Warsaw, Poland.

Published: December 2002

The study comprised strains of Candida albicans isolated from patients hospitalised in a tertiary care hospital during a 2-year period. In total 851 strains were cultured, including 379 (44.5%) strains from internal medicine patients, 243 (28.6%) from surgical patients and 229 (26.9%) from patients in the surgical intensive care unit. The strains were tested for susceptibility to the triazoles: fluconazole and itraconazole. There were 523 (61.5%) strains susceptible, 11 strains (1.3%) showed intermediate susceptibility and 317 (37.2%) were resistant to fluconazole, while 403 (47.3%) strains were susceptible, 43 (5.1%) intermediately susceptible and 405 (47.6%) resistant to itraconazole. Regular surveillance of fungal resistance patterns should be carried out and there should be prudent use of hospital triazole usage.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0924-8579(02)00246-7DOI Listing

Publication Analysis

Top Keywords

candida albicans
8
susceptibility triazoles
8
strains susceptible
8
strains
7
epidemiology clinical
4
clinical isolates
4
isolates candida
4
albicans susceptibility
4
triazoles study
4
study comprised
4

Similar Publications

Background: Candidiasis can be present as a cutaneous, mucosal, or deep-seated organ infection, which is caused by more than 20 types of Candida spp., with C. albicans being the most common.

View Article and Find Full Text PDF

A novel molecular design based on a quinazolinone scaffold was developed the attachment of aryl alkanesulfonates to the quinazolinone core through a thioacetohydrazide azomethine linker, leading to a new series of quinazolinone-alkanesulfonates 5a-r. The antimicrobial properties of the newly synthesized quinazolinone derivatives 5a-r were investigated to examine their bactericidal and fungicidal activities against bacterial pathogens like , (Gram-positive), , , (Gram-negative), in addition to (unicellular fungal). The tested compounds demonstrated reasonable bactericidal activities compared to standard drugs.

View Article and Find Full Text PDF

In this work, microalgae-based zinc oxide nanoparticles loaded with electrospun polyvinyl alcohol (PVA)/sodium alginate (SA) nanofibers were fabricated by electro-spinner. PVA/SA fibrous mats were crosslinked by citric acid, which enhanced their thermal stability and swelling behavior. Green-synthesized ZnO NPs were laboratory synthesized and characterized by FTIR, XRD, EDX, SEM, TEM and TGA analyses.

View Article and Find Full Text PDF

Microspheres based on galactomannan and Spondias purpurea L. extract to increase antifungal and antibiofilm efficacy against Candida spp.

Int J Biol Macromol

January 2025

Laboratory of Polymers and Materials Innovation, Department of Organic and Inorganic Chemistry, Sciences Center, Federal University of Ceará, Campus of Pici, Zip Code 60440-900 Fortaleza, CE, Brazil. Electronic address:

The ongoing problem of an increasing resistance of Candida spp. to available antifungals, has made it necessary the search for new therapeutic alternatives. The aim of this work was to develop a microsphere based on Caesalpinia ferrea galactomannan and Spondias purpurea L.

View Article and Find Full Text PDF

Introduction: Antimicrobial resistance and free radical-mediated oxidative stress and inflammation involved in many pathological processes have become treatment challenges. One strategy is to search for antimicrobial and antioxidant ingredients from natural aromatic plants. This study established a rapid and high-throughput effect-component analysis method to screen active ingredients from Ligusticum chuanxiong essential oil (CXEO).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!